Literature DB >> 9371979

Natural history and determinants of clinical severity of sickle cell disease.

G R Serjeant1.   

Abstract

Some of the factors determining the extremely variable clinical course of homozygous sickle cell disease are being identified. Genetic factors include alpha-thalassemia, beta-globin gene haplotypes, heterocellular hereditary persistence of fetal hemoglobin, and high total hemoglobin. Other factors include a variety of environmental variables and socioeconomic status. These risk factors, when occurring in conjunction with apparently random precipitating events, produce features of the disease. Many complications--which are age specific, with highest morbidity and mortality in the first 5 years--may be prevented by specific education and prophylaxis. Current median survival in individuals with sickle cell disease in the United States is approximately 40 to 50 years, at which age the major determinants of mortality are chronic end organ damage of the lungs and kidneys.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9371979     DOI: 10.1097/00062752-199502020-00001

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  15 in total

1.  Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic β-type globin genes.

Authors:  Shuaiying Cui; Osamu Tanabe; Michael Sierant; Lihong Shi; Andrew Campbell; Kim-Chew Lim; James Douglas Engel
Journal:  Blood       Date:  2015-01-05       Impact factor: 22.113

2.  Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study.

Authors:  K Maxwell; A Streetly; D Bevan
Journal:  BMJ       Date:  1999-06-12

3.  Association of circulating transcriptomic profiles with mortality in sickle cell disease.

Authors:  Ankit A Desai; Zhengdeng Lei; Neil Bahroos; Mark Maienschein-Cline; Santosh L Saraf; Xu Zhang; Binal N Shah; Seyed M Nouraie; Taimur Abbasi; Amit R Patel; Roberto M Lang; Yves Lussier; Joe G N Garcia; Victor R Gordeuk; Roberto F Machado
Journal:  Blood       Date:  2017-04-03       Impact factor: 22.113

4.  Spectrum of musculo-skeletal disorders in sickle cell disease in Lagos, Nigeria.

Authors:  Rufai A Balogun; Dike C Obalum; Suleiman O Giwa; Thomas O Adekoya-Cole; Chidiebere N Ogo; George O Enweluzo
Journal:  J Orthop Surg Res       Date:  2010-01-18       Impact factor: 2.359

5.  Sickle cell disease in central India.

Authors:  Archana B Patel; Ambarish M Athavale
Journal:  Indian J Pediatr       Date:  2004-09       Impact factor: 1.967

6.  Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype.

Authors:  A Driss; K O Asare; J M Hibbert; B E Gee; T V Adamkiewicz; J K Stiles
Journal:  Genomics Insights       Date:  2009-07-30

7.  Gene-centric association study of acute chest syndrome and painful crisis in sickle cell disease patients.

Authors:  Geneviève Galarneau; Sean Coady; Melanie E Garrett; Neal Jeffries; Mona Puggal; Dina Paltoo; Karen Soldano; Antonio Guasch; Allison E Ashley-Koch; Marilyn J Telen; Abdullah Kutlar; Guillaume Lettre; George J Papanicolaou
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

8.  Current management of sickle cell anemia.

Authors:  Patrick T McGann; Alecia C Nero; Russell E Ware
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

9.  Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.

Authors:  Hassana Fathallah; Ali Taher; Ali Bazarbachi; George F Atweh
Journal:  Blood Cells Mol Dis       Date:  2009-04-05       Impact factor: 3.039

10.  Experiences of hospital care and treatment-seeking behavior for pain from sickle cell disease: qualitative study.

Authors:  K Maxwell; A Streetly; D Bevan
Journal:  West J Med       Date:  1999-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.